Psychopharmacological Studies of 5-(4-Methylphenyl)-3-Phenylimidazolidine-2,4-dione (HPA-05) in Mice

Paula Regina Rodrigues Salgado

Abstract

A significant proportion of the pharmaceutical market is currently made up of organic compounds, the majority of which are heterocyclic. Of these, the hydantoins merit particular attention due to their numerous biological. The purpose of our research was to study the acute toxicity and the effects of the imidazolidine derivative 5-(4-methylphenyl)-3-phenylimidazolidine-2,4-dione (HPA-05), obtained by organic synthesis, on the central nervous system of mice. The psychopharmacological study of HPA-05 (50, 100 and 200 mg/kg, i.p.) on mice was assessed in the open field test, rota-rod test, elevated plus-maze test, pentylenetetrazole induced seizure test and maximal electroshock seizure test. The median lethal dose (LD50) could not be determined since it exceeds the maximum dose used in this study (1000 mg/kg, i.p.). In the open field test, HPA-05 was found to have the profile of Central nervous system depression. HPA-05 (50, 100 and 200 mg/kg, i.p.) did not alter the animals’ motor coordination, as evaluated in the rotarod test. In the elevated plus maze test, no behavioral change indicative of a possible anxiolytic effect was found. The results with HPA-05 also showed that this compound effectively increases the latency time until the onset of seizures induced by pentylenetetrazole or in the maximal electroshock seizure test. Therefore, considering this set of results, it is reasonable to suggest that HPA-05 has a profile similar to that of depressants and anticonvulsants, without affecting motor function.

Relevant Publications in Journal of Chemical and Pharmaceutical Research